Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 15, 2025 08:00 ET | Source: Tiziana Life Sciences Ltd.

Department of Defense Awards Grant to Advance Tiziana Life Sciences Intranasal Anti-CD3 Therapy for Spinal Cord Injury

BOSTON, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
August 19, 2025 08:12 ET | Source: Jupiter Neurosciences, Inc.

Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador

Partnership expands momentum for launch of new longevity supplement line powered by clinical science and performance-driven innovation Jupiter, Florida, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Jupiter...
August 12, 2025 22:30 ET | Source: Custom Market Insights

[Latest] US Personalized Medicine Market Size/Share Worth USD 252.93 Billion by 2034 at a 17.32% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

Austin, TX, USA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “US Personalized Medicine Market Size, Trends and Insights By Product...
August 07, 2025 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

RAP-219 Phase 2a trial in patients with drug-resistant focal onset seizures is fully enrolled and on track for topline results in September 2025Phase 2 trial of RAP-219 in bipolar mania has been...
July 29, 2025 08:00 ET | Source: Therini Bio, Inc.

Therini Bio Announces First Patient Dosed in Phase 1b Trial of THN391 in Alzheimer’s Disease

Therini Bio announced the dosing of the first patient in their Phase 1b trial evaluating THN391 in Alzheimer's Disease
July 10, 2025 03:00 ET | Source: Vect-Horus

Secarna Pharmaceuticals et Vect-Horus annoncent un programme de recherche pour le transport ciblé des thérapies visant l’ARN pour traiter les maladies du système nerveux central.

Ce partenariat permet d'associer la technologie OligoCreator® de Secarna avec la plateforme VECTrans® de Vect-Horus, afin de rendre possible le transport systémique des oligonucléotides à travers la...
July 10, 2025 03:00 ET | Source: Vect-Horus

Secarna Pharmaceuticals and Vect-Horus Announce Research Collaboration to Advance Systemic Delivery of RNA-Targeted Therapeutics for CNS Disorders

The partnership combines Secarna’s OligoCreator® technology with Vect-Horus’ VECTrans® platform to enable systemic delivery of oligonucleotide therapies across the blood-brain barrierThis...
June 23, 2025 07:00 ET | Source: Denovo Biopharma

Denovo Biopharma LLC Enters into an Exclusive Out-License Agreement with Chuang Yi Global Asset Management Co., Ltd. for Biomarker-Guided DB104 (liafensine) in Patients with Treatment-Resistant Depression (TRD) in Taiwan

SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- Denovo Biopharma LLC, a pioneer in applying precision medicine to development of innovative drugs, today announced that it has out-licensed its...
June 10, 2025 14:00 ET | Source: Bexorg

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

Bexorg Announces Multi-Program Research Collaboration with Biohaven to Enhance New CNS Drug Discovery and Development
June 06, 2025 07:00 ET | Source: Denovo Biopharma

Denovo Biopharma Announces Formation of Neuroscience Scientific Advisory Board to Advance Precision Medicine in Depression

- Scientific Advisory Board brings together distinguished experts in neuroscience to support Denovo’s CNS development programs, including the Phase 3-ready lead program, biomarker-guided DB104...